Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2016 01:33 ET | Source: MorphoSys AG

MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeutics

MARTINSRIED / MUNICH, Germany, May 24, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and The University of Texas MD Anderson Cancer Center today...
May 19, 2016 01:34 ET | Source: MorphoSys AG

MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2016

MARTINSRIED / MUNICH, Germany, May 19, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the publication of three abstracts which were...
May 04, 2016 05:35 ET | Source: MorphoSys AG

MorphoSys to Present at Three Upcoming Conferences

MARTINSRIED / MUNICH, Germany, May 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Deutsche Bank 41st Annual...
May 03, 2016 01:08 ET | Source: MorphoSys AG

MorphoSys AG Reports Results for the First Three Months of 2016

MARTINSRIED / MUNICH, Germany, May 3, 2016 (GLOBE NEWSWIRE) -- Financial Guidance 2016 Confirmed Conference call and webcast (in English) today at 2:00pm CEST (1:00pm BST/8:00am EDT) MorphoSys AG...
April 27, 2016 08:06 ET | Source: MorphoSys AG

MorphoSys to Host Q1 2016 Conference Call on May 3, 2016

Martinsried / Munich, Germany, April 27, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months' 2016 results on May 3, 2016 at 7:00 am...
April 21, 2016 02:03 ET | Source: MorphoSys AG

MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab

MARTINSRIED / MUNICH, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Novartis has confirmed that a...
April 21, 2016 02:01 ET | Source: MorphoSys AG

Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab

MARTINSRIED / MUNICH, Germany, April 21, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its partner Novartis has confirmed that a...
April 20, 2016 09:32 ET | Source: MorphoSys AG

MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on June 2, 2016 according to sec. 121 para. 4a AktG with the objective of Europe-wide distribution

MARTINSRIED / MUNICH, Germany, April 20, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG Martinsried/Planegg Securities Code Number: 663200 ISIN: DE0006632003 Convenience Translation: The text decisive for...
April 18, 2016 05:45 ET | Source: MorphoSys AG

MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis

MARTINSRIED / MUNICH, Germany, April 18, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that its licensing partner GSK has initiated a...
April 07, 2016 01:33 ET | Source: MorphoSys AG

MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106

MARTINSRIED / MUNICH, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext & NASDAQ: GLPG) announced today that...